Data_Sheet_3_NK1.1 Expression Defines a Population of CD4+ Effector T Cells Displaying Th1 and Tfh Cell Properties That Support Early Antibody Production During Plasmodium yoelii Infection.PDF
Early plasmablast induction is a hallmark of Plasmodium infection and is thought to contribute to the control of acute parasite burden. Although long understood to be a T-cell dependent phenomenon, regulation of early plasmablast differentiation, however, is poorly understood. Here, we identify a population of CD4+ T cells that express the innate NK cell marker NK1.1 as an important source of T cell help for early plasmablast and parasite-specific Ab production. Interestingly, NK1.1+ CD4+ T cells arise from conventional, naive NK1.1− CD4+ T cells, and their generation is independent of CD1d but critically reliant on MHC-II. CD4+ T cells that express NK1.1 early after activation produce IFN-γ and IL-21, and express the follicular helper T (Tfh) cell markers ICOS, PD-1 and CXCR5 more frequently than NK1.1− CD4+ T cells. Further analysis of this population revealed that NK1.1+ Tfh-like cells were more regularly complexed with plasmablasts than NK1.1− Tfh-like cells. Ultimately, depletion of NK1.1+ cells impaired class-switched parasite-specific antibody production during early Plasmodium yoelii infection. Together, these data suggest that expression of NK1.1 defines a population of rapidly expanding effector CD4+ T cells that specifically promote plasmablast induction during Plasmodium infection and represent a subset of T cells whose modulation could promote effective vaccine design.
History
References
- https://doi.org//10.4049/jimmunol.1203067
- https://doi.org//10.1016/j.vaccine.2015.07.091
- https://doi.org//10.1073/pnas.1006662107
- https://doi.org//10.1038/nri2451
- https://doi.org//10.1146/annurev.immunol.25.022106.141711
- https://doi.org//10.1038/nri1309
- https://doi.org//10.1126/science.283.5399.225
- https://doi.org//10.1002/eji.200323666
- https://doi.org//10.1128/IAI.01818-06
- https://doi.org//10.1128/IAI.00539-10
- https://doi.org//10.1073/pnas.1323405111
- https://doi.org//10.4049/jimmunol.165.7.3673
- https://doi.org//10.1038/srep14124
- https://doi.org//10.4049/jimmunol.1502199
- https://doi.org//10.4049/jimmunol.1403206
- https://doi.org//10.1038/srep00118
- https://doi.org//10.1016/S0165-2478(03)00152-4
- https://doi.org//10.4049/jimmunol.1701316
- https://doi.org//10.1006/expr.1996.4132
- https://doi.org//10.1371/journal.ppat.1004715
- https://doi.org//10.1016/j.exppara.2006.04.003
- https://doi.org//10.1371/journal.pone.0144654
- https://doi.org//10.1016/j.immuni.2008.05.009
- https://doi.org//10.1016/j.immuni.2011.03.023
- https://doi.org//10.1038/ni.3050
- https://doi.org//10.4049/jimmunol.1402157
- https://doi.org//10.1002/ijc.25397
- https://doi.org//10.4049/jimmunol.173.2.945
- https://doi.org//10.1006/cimm.2001.1833
- https://doi.org//10.4049/jimmunol.164.4.2009
- https://doi.org//10.1016/j.exger.2007.05.002
- https://doi.org//10.1016/j.celrep.2017.10.077
- https://doi.org//10.1016/j.celrep.2015.12.006
- https://doi.org//10.1126/sciimmunol.aal2192
- https://doi.org//10.3389/fimmu.2016.00006
- https://doi.org//10.1016/j.it.2014.09.008
- https://doi.org//10.3389/fimmu.2013.00362
- https://doi.org//10.1126/science.2399464
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity